GSK

News

GSK enlists local aid for Chinese rollout of hep B drug

GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under NMPA review.

News

GSK bolts on siRNA drug from China's SiranBio in $1bn deal

GSK has extended its pipeline of siRNA drugs once again by licensing an ALK7-targeted therapy for cardiometabolic diseases from SiranBio.

News

First-quarter sales strength buoys new GSK CEO Miels

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new CEO Luke Miels.

News

GSK eyes October FDA verdict on chronic hep B drug

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.

News

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.

News

Multiple myeloma drug Blenrep backed for wider NHS use

The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.

GSK enlists local aid for Chinese rollout of hep B drug

GSK bolts on siRNA drug from China's SiranBio in $1bn deal

First-quarter sales strength buoys new GSK CEO Miels

GSK eyes October FDA verdict on chronic hep B drug

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

Multiple myeloma drug Blenrep backed for wider NHS use

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks